Cancer Research Cancer Epigenetics  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walczak, H.
Right arrow Articles by Krammer, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walczak, H.
Right arrow Articles by Krammer, P. H.
[Cancer Research 60, 3051-3057, June 1, 2000]
© 2000 American Association for Cancer Research


Tumor Biology

Tumor Necrosis Factor-related Apoptosis-inducing Ligand Retains Its Apoptosis-inducing Capacity on Bcl-2- or Bcl-xL-overexpressing Chemotherapy-resistant Tumor Cells1

Henning Walczak2, Axel Bouchon3, Heiko Stahl and Peter H. Krammer

Tumor Immunology Program, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor family and has recently been shown to exert tumoricidal activity in vivo in the absence of any observable toxicity. The signaling pathways triggered by TRAIL stimulation and the mechanisms involved in resistance against TRAIL-mediated apoptosis are still poorly defined. We show here that TRAIL-induced apoptosis involves late dissipation of mitochondrial membrane potential ({Delta}{Psi}m) and cytochrome c release. These events follow activation of caspase-8 and caspase-3 and induction of DNA fragmentation. In addition, caspase-8-deficient cells are resistant against TRAIL-induced apoptosis, and inhibition of caspase-8 but not caspase-9 prevents mitochondrial permeability transition and apoptosis. In contrast, various Bcl-2- or Bcl-xL-overexpressing tumor cell lines are sensitive to TRAIL-induced apoptosis; however, they show a delay in TRAIL-induced mitochondrial permeability transition compared with control transfectants. This indicates that TRAIL-induced apoptosis depends on caspase-8 activation rather than on the disruption of mitochondrial integrity. Because most chemotherapeutic drugs used in the treatment of malignancies lead to apoptosis primarily by engagement of the mitochondrial proapoptotic machinery, we tested whether drug-resistant tumor cells retain sensitivity for TRAIL-induced apoptosis. Tumor cells overexpressing Bcl-2 or Bcl-xL become resistant to apoptosis induced by the chemotherapeutic drug etoposide. However, these cells are not protected or are only marginally protected against TRAIL-induced apoptosis. Thus, TRAIL may still kill tumors that have acquired resistance to chemotherapeutic drugs by overexpression of Bcl-2 or Bcl-xL. These data will influence future treatment strategies involving TRAIL.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
U. M. Schneiders, L. Schyschka, A. Rudy, and A. M. Vollmar
BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells
Mol. Cancer Ther., October 1, 2009; 8(10): 2914 - 2925.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
C. Jursik, M. Prchal, R. Grillari-Voglauer, K. Drbal, E. Fuertbauer, H. Jungfer, W. H. Albert, E. Steinhuber, T. Hemetsberger, J. Grillari, et al.
Large-Scale Production and Characterization of Novel CD4+ Cytotoxic T Cells with Broad Tumor Specificity for Immunotherapy
Mol. Cancer Res., March 1, 2009; 7(3): 339 - 353.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Fakler, S. Loeder, M. Vogler, K. Schneider, I. Jeremias, K.-M. Debatin, and S. Fulda
Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance
Blood, February 19, 2009; 113(8): 1710 - 1722.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Wang, T. Chen, N. Zhang, M. Yang, B. Li, X. Lu, X. Cao, and C. Ling
Melittin, a Major Component of Bee Venom, Sensitizes Human Hepatocellular Carcinoma Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Activating CaMKII-TAK1-JNK/p38 and Inhibiting I{kappa}B{alpha} Kinase-NF{kappa}B
J. Biol. Chem., February 6, 2009; 284(6): 3804 - 3813.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
N. Chetoui, K. Sylla, J.-V. Gagnon-Houde, C. Alcaide-Loridan, D. Charron, R. Al-Daccak, and F. Aoudjit
Down-Regulation of Mcl-1 by Small Interfering RNA Sensitizes Resistant Melanoma Cells to Fas-Mediated Apoptosis
Mol. Cancer Res., January 1, 2008; 6(1): 42 - 52.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. K. Rowinsky
Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Activating Agents
J. Clin. Oncol., December 20, 2005; 23(36): 9394 - 9407.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z. Wang, J. Sampath, S. Fukuda, and L. M. Pelus
Disruption of the Inhibitor of Apoptosis Protein Survivin Sensitizes Bcr-abl-Positive Cells to STI571-Induced Apoptosis
Cancer Res., September 15, 2005; 65(18): 8224 - 8232.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Shiraishi, T. Yoshida, S. Nakata, M. Horinaka, M. Wakada, Y. Mizutani, T. Miki, and T. Sakai
Tunicamycin Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Human Prostate Cancer Cells
Cancer Res., July 15, 2005; 65(14): 6364 - 6370.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Baumann, A. Dostert, N. Novac, A. Bauer, W. Schmid, S. C. Fas, A. Krueger, T. Heinzel, S. Kirchhoff, G. Schutz, et al.
Glucocorticoids inhibit activation-induced cell death (AICD) via direct DNA-dependent repression of the CD95 ligand gene by a glucocorticoid receptor dimer
Blood, July 15, 2005; 106(2): 617 - 625.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. Dicker, A. P. Kater, T. Fukuda, and T. J. Kipps
Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells
Blood, April 15, 2005; 105(8): 3193 - 3198.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. A. Sinicrope, R. C. Penington, and X. M. Tang
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis Is Inhibited by Bcl-2 but Restored by the Small Molecule Bcl-2 Inhibitor, HA 14-1, in Human Colon Cancer Cells
Clin. Cancer Res., December 15, 2004; 10(24): 8284 - 8292.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
X. Liu, P. Yue, Z. Zhou, F. R. Khuri, and S.-Y. Sun
Death Receptor Regulation and Celecoxib-Induced Apoptosis in Human Lung Cancer Cells
J Natl Cancer Inst, December 1, 2004; 96(23): 1769 - 1780.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Izeradjene, L. Douglas, A. B. Delaney, and J. A. Houghton
Casein Kinase I Attenuates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Regulating the Recruitment of Fas-Associated Death Domain and Procaspase-8 to the Death-Inducing Signaling Complex
Cancer Res., November 1, 2004; 64(21): 8036 - 8044.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Izeradjene, L. Douglas, A. Delaney, and J. A. Houghton
Influence of Casein Kinase II in Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Human Rhabdomyosarcoma Cells
Clin. Cancer Res., October 1, 2004; 10(19): 6650 - 6660.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. Sonnemann, V. Gekeler, A. Sagrauske, C. Muller, H.-P. Hofmann, and J. F. Beck
Down-regulation of protein kinase C{eta} potentiates the cytotoxic effects of exogenous tumor necrosis factor-related apoptosis-inducing ligand in PC-3 prostate cancer cells
Mol. Cancer Ther., July 1, 2004; 3(7): 773 - 781.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Ballestrero, A. Nencioni, D. Boy, I. Rocco, A. Garuti, G. S. Mela, L. Van Parijs, P. Brossart, S. Wesselborg, and F. Patrone
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Anticancer Drugs to Overcome Chemoresistance in Antiapoptotic Bcl-2 Family Members Expressing Jurkat Cells
Clin. Cancer Res., February 15, 2004; 10(4): 1463 - 1470.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. L. Hayward, J. S. Macpherson, J. Cummings, B. P. Monia, J. F. Smyth, and D. I. Jodrell
Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect
Mol. Cancer Ther., February 1, 2004; 3(2): 169 - 178.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
V. M. Dirsch, I. M. Muller, S. T. Eichhorst, G. R. Pettit, Y. Kamano, M. Inoue, J.-P. Xu, Y. Ichihara, G. Wanner, and A. M. Vollmar
Cephalostatin 1 Selectively Triggers the Release of Smac/DIABLO and Subsequent Apoptosis That Is Characterized by an Increased Density of the Mitochondrial Matrix
Cancer Res., December 15, 2003; 63(24): 8869 - 8876.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
X. Liao, L. Zhang, J. B. Thrasher, J. Du, and B. Li
Glycogen synthase kinase-3{beta} suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer
Mol. Cancer Ther., November 1, 2003; 2(11): 1215 - 1222.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Chawla-Sarkar, J. A. Bauer, J. A. Lupica, B. H. Morrison, Z. Tang, R. K. Oates, A. Almasan, J. A. DiDonato, E. C. Borden, and D. J. Lindner
Suppression of NF-{kappa}B Survival Signaling by Nitrosylcobalamin Sensitizes Neoplasms to the Anti-tumor Effects of Apo2L/TRAIL
J. Biol. Chem., October 10, 2003; 278(41): 39461 - 39469.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Ruiz-Ruiz, G. Robledo, E. Cano, J. M. Redondo, and A. Lopez-Rivas
Characterization of p53-mediated Up-regulation of CD95 Gene Expression upon Genotoxic Treatment in Human Breast Tumor Cells
J. Biol. Chem., August 22, 2003; 278(34): 31667 - 31675.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. L. Hayward, J. S. Macpherson, J. Cummings, B. P. Monia, J. F. Smyth, and D. I. Jodrell
Antisense Bcl-xl Down-Regulation Switches the Response to Topoisomerase I Inhibition from Senescence to Apoptosis in Colorectal Cancer Cells, Enhancing Global Cytotoxicity
Clin. Cancer Res., July 1, 2003; 9(7): 2856 - 2865.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Kandasamy, S. M. Srinivasula, E. S. Alnemri, C. B. Thompson, S. J. Korsmeyer, J. L. Bryant, and R. K. Srivastava
Involvement of Proapoptotic Molecules Bax and Bak in Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Mitochondrial Disruption and Apoptosis: Differential Regulation of Cytochrome c and Smac/DIABLO Release
Cancer Res., April 1, 2003; 63(7): 1712 - 1721.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
V. Hietakangas, M. Poukkula, K. M. Heiskanen, J. T. Karvinen, L. Sistonen, and J. E. Eriksson
Erythroid Differentiation Sensitizes K562 Leukemia Cells to TRAIL-Induced Apoptosis by Downregulation of c-FLIP
Mol. Cell. Biol., February 15, 2003; 23(4): 1278 - 1291.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. Leverkus, M. R. Sprick, T. Wachter, T. Mengling, B. Baumann, E. Serfling, E.-B. Brocker, M. Goebeler, M. Neumann, and H. Walczak
Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation
Mol. Cell. Biol., February 1, 2003; 23(3): 777 - 790.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
A. B. Werner, E. de Vries, S. W. G. Tait, I. Bontjer, and J. Borst
TRAIL Receptor and CD95 Signal to Mitochondria via FADD, Caspase-8/10, Bid, and Bax but Differentially Regulate Events Downstream from Truncated Bid
J. Biol. Chem., October 18, 2002; 277(43): 40760 - 40767.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Javelaud and F. Besancon
Inactivation of p21WAF1Sensitizes Cells to Apoptosis via an Increase of Both p14ARF and p53 Levels and an Alteration of the Bax/Bcl-2 Ratio
J. Biol. Chem., September 27, 2002; 277(40): 37949 - 37954.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Tang, Y. J. Sun, E. Half, M. T. Kuo, and F. Sinicrope
Cyclooxygenase-2 Overexpression Inhibits Death Receptor 5 Expression and Confers Resistance to Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Human Colon Cancer Cells
Cancer Res., September 1, 2002; 62(17): 4903 - 4908.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Weber, M. Lu, L. Andera, H. Lahm, N. Gellert, M. W. Fariss, V. Korinek, W. Sattler, D. S. Ucker, A. Terman, et al.
Vitamin E Succinate Is a Potent Novel Antineoplastic Agent with High Selectivity and Cooperativity with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (Apo2 Ligand) in Vivo
Clin. Cancer Res., March 1, 2002; 8(3): 863 - 869.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Secchiero, A. Gonelli, C. Celeghini, P. Mirandola, L. Guidotti, G. Visani, S. Capitani, and G. Zauli
Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies
Blood, October 1, 2001; 98(7): 2220 - 2228.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
V. M. Dirsch, H. Stuppner, and A. M. Vollmar
Helenalin Triggers a CD95 Death Receptor-independent Apoptosis That Is Not Affected by Overexpression of Bcl-xL or Bcl-2
Cancer Res., August 1, 2001; 61(15): 5817 - 5823.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. L. Jelachich and H. L. Lipton
Theiler's Murine Encephalomyelitis Virus Induces Apoptosis in Gamma Interferon-Activated M1 Differentiated Myelomonocytic Cells through a Mechanism Involving Tumor Necrosis Factor Alpha (TNF-{alpha}) and TNF-{alpha}-Related Apoptosis-Inducing Ligand
J. Virol., July 1, 2001; 75(13): 5930 - 5938.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Özören, K. Kim, T. F. Burns, D. T. Dicker, A. D. Moscioni, and W. S. El-Deiry
The Caspase 9 Inhibitor Z-LEHD-FMK Protects Human Liver Cells while Permitting Death of Cancer Cells Exposed to Tumor Necrosis Factor-related Apoptosis-inducing Ligand
Cancer Res., November 1, 2000; 60(22): 6259 - 6265.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
D. Bernard, B. Quatannens, B. Vandenbunder, and C. Abbadie
Rel/NF-kappa B Transcription Factors Protect against Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Up-regulating the TRAIL Decoy Receptor DcR1
J. Biol. Chem., July 13, 2001; 276(29): 27322 - 27328.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. F. Burns and W. S. El-Deiry
Identification of Inhibitors of TRAIL-induced Death (ITIDs) in the TRAIL-sensitive Colon Carcinoma Cell Line SW480 Using a Genetic Approach
J. Biol. Chem., October 5, 2001; 276(41): 37879 - 37886.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.